This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brey, R.L. Articles by Teale, J.M. Search for Related Content PubMed PubMed Citation Articles by Brey, R.L. Articles by Teale, J.M. Social Bookmarking                         What's this?

Model for the neuromuscular complications of systemic lupus erythematosus

Department of Medicine (Neurology), The University of Texas Health Science Center at San Antonio, Texas, USA

S. Cote

Department of Medicine (Neurology), The University of Texas Health Science Center at San Antonio, Texas, USA

R. Barohn

Department of Medicine (Neurology), The University of Texas Health Science Center at San Antonio, Texas, USA

C. Jackson

Department of Medicine (Neurology), The University of Texas Health Science Center at San Antonio, Texas, USA

R. Crawley

Department of Laboratory Animal Resources, The University of Texas Health Science Center at San Antonio, Texas, USA

J.M. Teale

Department of Microbiology, The University of Texas Health Science Center at San Antonio. Texas, USA

The purpose of this study is to evaluate nerve and muscle physiology and histopathology in a murine lupus model. Muscle strength, compound muscle action potentials (distal latency and amplitude), proximal limb muscle, sciatic nerve and joint specimens were studied in MRL/lpr (lupus model) and MRL/++ (control) mice. MRL/lpr mice showed decreased muscle strength (P<10^-6 Wilcoxon rank sum), lower compound muscle action potential mean amplitude and prolonged distal latency (P = 0.005 and 0.042, Mann-Whitney U-test), and muscle and nerve inflammation (P = 0.002 and P = 0.037, Fisher's exact test) compared with MRL/++ mice. The MRL/lpr strain evaluated in this study demonstrated muscle weakness, abnormal motor nerve conduction studies and inflammation of both muscle and nerve. These features make it an excellent model for studying the neuromuscular complications of lupus.

Key Words: murine models • neuromuscular complications • inflammation nerve • conduction study

Lupus, Vol. 4, No. 3, 209-212 (1995)
DOI: 10.1177/096120339500400308


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A Katzav, J Chapman, and Y Shoenfeld CNS dysfunction in the antiphospholipid syndrome Lupus, December 1, 2003; 12(12): 903 - 907. [Abstract] [PDF]

				S Shrot, A Katzav, A D Korczyn, Y Litvinjuk, R Hershenson, C G Pick, M Blank, J Zaech, Y Shoenfeld, P Sirota, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies Lupus, November 1, 2002; 11(11): 736 - 743. [Abstract] [PDF]

				R. L. Brey, R. D. Abbott, J. D. Curb, D. S. Sharp, G. W. Ross, C. L. Stallworth, and S. J. Kittner {beta}2-Glycoprotein 1-Dependent Anticardiolipin Antibodies and Risk of Ischemic Stroke and Myocardial Infarction: The Honolulu Heart Program Stroke, August 1, 2001; 32(8): 1701 - 1706. [Abstract] [Full Text] [PDF]

				A Katzav, C G Pick, A D Korczyn, E Oest, M Blank, Y Shoenfeld, and J Chapman Hyperactivity in a mouse model of the antiphospholipid syndrome Lupus, July 1, 2001; 10(7): 496 - 499. [Abstract] [PDF]

				J Chapman, M Cohen-Armon, Y Shoenfeld, and A D Korczyn Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes Lupus, February 1, 1999; 8(2): 127 - 133. [Abstract] [PDF]

				Y. Shoenfeld and L. Ziporen Review : Lessons from experimental APS models Lupus, January 1, 1998; 7(2_suppl): S158 - S161. [Abstract] [PDF]

				R. Brey, A. Amato, K. Kagan-Hallet, C. Rhine, and C. Stallworth Anti-Intercellular Adhesion Molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice Lupus, January 1, 1997; 6(8): 645 - 651. [Abstract] [PDF]